Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy.

There is a lack of investigation into the biological characteristics and preoperative systemic therapy (PST) for occult breast cancer (OBC). For this study, departmental records in Breast Disease Center of Peking University First Hospital from January 2008 to December 2015 were retrospectively reviewed to identify cases of OBC. Eleven cases were included, and all patients were female, with a median age of 56 (range: 29-75) years. The sensitivity of magnetic resonance imaging (MRI) was 100%, and the false positive rate was 33.3%. Based on histologic analysis of the axillary node, 9 (81.8%) cases were grade 3, and 2 (18.2%) cases were grade 2; 4 (36.4%) cases were ≥10% estrogen receptor (ER) positive and 6 (54.5%) human epidermal growth receptor 2 (HER2) positive. Nine cases (81.8%) exhibited over 30% Ki67 expression. PST was performed in 5 of the 11 cases. The lymph node response rate was 100% (5/5), but no complete remission was achieved. In conclusion, aggressive subtypes were predominant among the included cases, and PST should be considered for OBC treatment options.

Introduction

Axillary metastases are the first indication of occult breast cancer (OBC) in less than 1% (1) of breast cancer patients. The first case of axillary presentation in breast cancer was detected by Halsted in 1907 (2), and many studies have since indicated that the prognosis of patients presenting with OBC is generally better than that reported for stage II (TxN1-2M0) breast cancer (3). However, to date no studies have described the biological characteristics of axillary metastasis in detail, and few studies have discussed preoperative systemic therapy (PST) options for patients. Due to the low incidence of OBC, previous studies were performed retrospectively, and optimal treatment approaches have yet to be established. Here, we present our experience about OBC in Breast Disease Center of Peking University First Hospital.

Case presentation

From January 2008 to December 2015, 2,705 cases were diagnosed as primary breast cancer in Breast Disease Center of Peking University First Hospital. Eleven (0.4%) cases presented as axillary metastasis, with no foci detected in the ipsilateral breast on bilateral ultrasound and mammography. All cases were diagnosed based on histopathological reports of axillary lymph node adenocarcinoma-compatible mammary carcinoma. All patients were female with the median follow-up period was 26 (range, 6–96) months; and the median age was 56 (range, 29–75) years. Among these cases, one patient had a family history of breast cancer. At the time of diagnosis, one case presented with metastasis in the mediastinal and retroperitoneal lymph nodes and in the liver. The study was approved by the Ethics Committee of the Peking University First Hospital.

Magnetic resonance imaging (MRI)

Of the 11 patients, 9 agreed to MRI, and we found abnormalities in the ipsilateral breast in 4 of these patients. In one of the 5 cases with negative findings, surgery was not accepted because of the stage IV diagnosis; this case was excluded from our analysis without pathology evidence. Among the 4 patients with abnormal MRI findings, no invasive or in situ tumors were found by surgery in two, whereas one had invasive ductal cancer and one fibrosis after PST. The sensitivity of MRI was 100% (2/2+0), and the false positive rate was 33.3% (2/2+4).

Histologic-pathological characters of axillary lymph nodes

In this study, lymphatic pathology was obtained via B-scanultrasound (GE S60)-guided core needle biopsy (16G, Bard Urological) in all cases prior to treatment. Histological grade was evaluated according to the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system (4).

For all patients, immunohistochemistry (IHC) staining for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2) and Ki67 were performed on consecutive tissue sections from the nodal disease. ER and PR status was classified as negative (lack of any ER and PR immunoreactivity or <1% tumor cell immunoreactivity, with positive inner control) or positive (≥1% tumor cell immunoreactivity) (5). Among those classified as positive, we defined samples as uncertain endocrine responsiveness (ER and/or PR <10% of cells positive) and endocrine responsiveness (both ER and PR ≥10% of cells positive) (6). The value of the Ki67 labeling index was divided into low (<14%) and high (≥14%) (7). Only intense and complete membrane staining in >10% of the tumor cells was considered as HER2 overexpression (3+). Fluorescence in situ hybridization (FISH) assays were performed in cases with IHC equivocal (2+) to identify cases with gene amplification as HER2 to chromosome 17 centromere ratio ≥2 (8).

We defined the clinicopathological surrogate subtypes of breast cancer according to the 2013 St. Gallen consensus (9) through IHC evaluation of ER, PR, HER2 and Ki67.

All 11 cases were subjected to lymphatic pathology before treatment and were found to be invasive adenocarcinoma considered to have derived from the mammary gland, as based on combined IHC and clinical features. Histologic analysis of the axillary node showed that 9 of the 11 (81.8%) cases were G3; 2 (18.2%) cases were G2, and none were G1. Of the 11 patients, 6 were ER negative, 1 was 2% weakly positive, and 4 were ≥10% positive; among the last four, three patients were PR negative. Of the 11 patients, 8 were PR negative, 2 were 2% positive, and only one was ≥10% positive. HER2 overexpression was observed in 6 of the 11 patients. Most of the patients (81.8%, 9/11) had a high Ki67 index, over 30%, and 72.7% (8/11) were ≥70%. In contrast, only one patient had a Ki67 index lower than 14%. Defined as surrogate subtypes, no Luminal A-like subtype was found; 3 were triple negative, 3 were HER2 positive, and 5 were Luminal B-like (3 HER2 positive, 2 HER2 negative).

PST regimens and response evaluation

Patients who were HER2 positive were administered TCH (docetaxel 75 mg/m2, carboplatin AUC=5–6, trastuzumab 8 mg/kg in the first week and followed by 6 mg/kg every 3 weeks). The remaining patients were given TA (docetaxel 75 mg/m2 or paclitaxel 175 mg/m2, combined with epirubicin 75 mg/m2 every 3 weeks).

The clinical response was evaluated by ultrasound according to RECIST 1.1 (10). In addition, we evaluated the pathological response of the primary site according to the Miller-Payne grading system (11). The pathological response of the axillary lymph node, as proposed by Sataloff in 1995 (12), is presented in .

Other treatments

Regardless of whether PST was performed, modified radical mastectomy (MRM) with radiotherapy or axillary lymph node dissection (ALND) with radiotherapy (the whole breast included) was recommended. Other standard therapies, such as hormone therapy and an anti-HER2 regimen (TCH, as described above), were also commonly recommended.

Upon initial diagnosis, one case was at stage IV, with mediastinal lymph node, retroperitoneal lymph node and liver metastases. The patient underwent MRI, and no abnormality was found in the breast. This patient received a TCH regimen (6 cycles) and achieved a clinically complete response (CR). She underwent radiotherapy, instead of mastectomy and ALND, and insisted on treatment with trastuzumab every 3 weeks.

Of the other 10 cases, 5 patients accepted 6 cycles of PST (), and surgery (MRM) was then performed. Pathology after PST and surgery showed a 5 N-C response, except for one case in which we found a 2 cm fibrosis in the breast consistent with the abnormality on MRI. Four of the patients received radiotherapy, and only one refused. One of the 5 patients was HER2 positive, for whom one year of trastuzumab therapy was completed.

The other 5 cases underwent surgery directly. Two cases refused mastectomy, and only ALND was performed. Moreover, these 2 cases were HER2 positive but refused adjuvant chemotherapy, anti-HER2 therapy and radiotherapy. MRM was performed on the 3 other patients, 2 of whom were found to have invasive ductal cancer in the breast. One of the 3 MRM patients refused adjuvant chemotherapy and radiotherapy. The other two MRM patients were HER2 positive, and they accepted doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) as adjuvant chemotherapy. In addition, both patients refused trastuzumab therapy: one accepted adiotherapy, whereas the other refused. All ER- and/or PR-positive patients accepted hormone therapy.

Follow-up

The cases were followed up until July 2016, with a median follow-up period of 26 (range, 6–96) months. One patient on whom only ALND was performed showed ipsilateral breast cancer 11 months later. The case diagnosed as de novo stage IV, achieved a clinically CR after 6 cycles TCH. As of the last follow-up, CR was maintained, and the patient was undergoing continuous trastuzumab therapy for over 2 years. The others survived without recurrence or metastasis.

Discussion

Patients of OBC comprise a rare subset. After decades of retrospective studies, some experts’ opinions are trending toward the recommendation of MRM. However, controversy remains, as there are few reports describing biological markers, molecular typing and PST for OBC.

Although MRI is a good method for identifying abnormalities more sensitively than mammography or breast ultrasound, the technique has a high false positive rate [29% in one study (13)]. The same was shown in our study. In our study, 8 patients underwent MRM (with or without PST), and we found signs of primary breast foci in 3 of them. Only ALND without radiotherapy was performed in 2 cases, and ipsilateral breast cancer was found 11 months later in one of them. Hence, MRM or breast radiotherapy should be performed, regardless of the breast abnormality found on MRI. According to a recent meta-analysis (14), the effects of ALND with breast radiotherapy were equal to those of MRM.

PST is rarely reported in OBC. A single-institutional review (15) by MD Anderson reported data for 25 patients who met criteria for OBC and underwent PST. Moreover, some patients were subjected to excisional biopsy when first diagnosed, and the data for these cases did not differ from the data for cases with no positive lymph nodes after ALND. Hence, the high pathologic complete response (pCR) rate in the study remains to be explained. In our study, all patients underwent 4–6 cycles of PST and exhibited clinical and pathological responses, yet no pCR was achieved in cases with lymph nodes metastasis. PST is a good approach for evaluating therapeutic responses and may promote a deeper understanding of the biological behavior of OBC. Hence, further investigation is needed.

Previous studies have reported controversial conclusions about OBC prognosis, most indicating that OBC has a better prognosis compared to other breast cancers with lymph node metastasis (1). However, due to its rarity, few studies have investigated the biological characteristics of OBC. In our analysis, most cases showed biomarkers indicated worse prognosis as high histological grade, ER negative, HER2 overexpression, and a very high Ki67 index, ≥70%. Actually, only one case had local breast recurrence during follow-up. Indeed, even the patient diagnosed at stage IV with hepatic metastasis had a good response to therapy, with 33-month survival to date. Hence, more data are necessary to promote our understanding of the biological characteristics of OBC.

Conclusions

OBC is a rare form of breast cancer. Its biological characteristics have not been well described to date. PST might be considered as an effective therapy for patients with OBC.

Acknowledgements

This work is supported by grants of the Precision Medicine Special Project of National Key Research and Development Program of China (2016YFC0901302).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

1

Pathological response of axillary lymph node after PST

Axillary lymph node response	Definition
PST, primary systemic therapy.
N-A	Evidence of therapeutic effect, no metastatic disease
N-B	No nodal metastasis or therapeutic effect
N-C	Evidence of therapeutic effect, but nodal metastasis still present
N-D	Viable metastatic disease, no therapeutic effect

2

Clinical and pathological characteristics of cases

Case No.	1	2	3	4	5	6	7	8	9	10	11
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; PST, primary systemic therapy; MRM, modified radical mastectomy; ALND, axillary lymph node dissection; TCH, docetaxel 75 mg/m2, carboplatin AUC=5-6, trastuzumab 8 mg/kg in the first week followed by 6 mg/kg every 3 weeks; TA, docetaxel 75 mg/m2 or paclitaxel 175 mg/m2, combined with epirubicin 75 mg/m2 every 3 weeks; AC-T, doxorubicin and cyclophosphamide followed by paclitaxel; H, trastuzumab; AI, aromatase inhibitors; TAM, tamoxifen; Neg., negative; Pos., positive; Y, yes; N, no.
Age (year)	56	54	59	59	29	57	67	56	75	44	34
MRI finding	Neg.	Neg.	1.5 cm × 1.7 cm ×1.7 cm mass in the lateral lower quadrant of the right breast (false positive)	Neg.	1.4 cm × 2.0 cm ×2.4 cm mass in lateral upper quadrants of the right breast	Refused	Refused	0.7 cm × 0.8 cm × 0.7 cm mass in the upper quadrant of the right breast	Neg.	0.5 cm × 0.4 cm × 0.4 cm mass in the inner quadrant of the left breast (false positive)	Neg.
Grade	3	3	3	3	3	2	3	3	3	2	3
N stage	N1	N2	N3	N2	N2	N2	N1	N2	N1	N1	N2M1
ER	Neg.	2% weak Pos.	90% strong Pos.	85% middle Pos.	Neg.	Neg.	Neg.	Neg.	50% middle Pos.	40% middle Pos.	Neg.
PR	Neg.	2% middle Pos.	Neg.	Neg.	Neg.	Neg.	Neg.	Neg.	Neg.	85% strong Pos.	<1% weak Pos.
HER2	Neg.	Neg.	Neg.	Pos.	Neg.	Pos.	Neg.	Pos.	Pos.	Pos.	Pos.
Ki67	80%	90%	10%	70%	80%	40%	70%	80%	90%	25%	70%
PST	TA×4	TA×6	TA×6	TCH×6	TAC×6	N	N	N	N	N	TCH-H
Surgery	MRM	MRM	MRM	MRM	MRM	ALND	MRM	MRM	ALND	MRM	N
Post-surgery breast pathology	Sclerosing adenosis	Adenosis	Slight proliferation	Slight proliferation	G5, 2 cm fibrosis, no residual invasive ductal cancer and DCIS		A little diffuse invasive ductal cancer cells, difficult to measure T	0.4 cm invasive ductal cancer		Adenosis
Post-surgery LN pathology	1/19, with fibrosis	6/28, all of 6 LNs with fibrosis	13/29, with a little fibrosis	1/19, two with fibrosis	5/13, all the 5 LNs with fibrosis	7/15	1/10	4/18	1/15	3/20
LN pathological evaluation	N-C	N-C	N-C	N-C	N-C
Adjuvant chemotherapy	TA×2	N	N	N	N	Refused	Refused	AC-T		AC-T
Adjuvant anti-HER2	N	N	N	H to 1 year	N	Refused	N	Refused	Refused	Refused
Radiotherapy	Y	Y	Y	Refused	Y	Refused	Refused	Y	Refused	Refused	Refused
Endocrine therapy	N	AI	AI	AI	N	N		N	AI	TAM
Follow-up (month)	15	21	26	6	23	53	96	43	67	8	33
Events						11 months after ALND, ipsilateral breast cancer